CD20-targeting monoclonal antibody

This page covers all CD20-targeting monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD20.

Targets

CD20

Marketed (4)

• rituximab [MabThera/Rituxan] · Hoffmann-La Roche · Oncology, Immunology
  Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.
• Rituximab 375 · University Hospital, Toulouse · Oncology, Immunology
  Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.
• MabThera · Sandoz · Oncology, Immunology
  MabThera (rituximab) is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
• Rituximab (R) · National Cancer Institute (NCI) · Oncology, Immunology
  Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.

Phase 3 pipeline (10)

• Ocrelizumab Dose 1 · Genentech, Inc. · Immunology
  Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation.
• EU-Ocrevus · Celltrion · Immunology
  EU-Ocrevus is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.
• Ocrelizumab Injection [Ocrevus] · Fondation Ophtalmologique Adolphe de Rothschild · Immunology / Neurology
  Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation and demyelination.
• Ocrelizumab IV · Hoffmann-La Roche · Immunology
  Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation.
• Ocrevus-EU · Sandoz · Immunology/Neurology
  Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis.
• Perfusion of treatment Ocrelizumab · Rennes University Hospital · Immunology
  Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.
• Ocrelizumab SC · Hoffmann-La Roche · Immunology
  Ocrelizumab SC is a monoclonal antibody that targets CD20 on B cells.
• Originator rituximab - Rituxan ® or MabThera ® · Sandoz · Oncology, Immunology
  Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.
• Ocrelizumab (EU) · Amgen · Immunology
  Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.
• Ocrelizumab (CinnaGen, Iran) · Cinnagen · Immunology
  Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.